BIOA

MKT CAP:$614M

BioAge Labs, Inc.

Market Cap

$614M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$17.24+$4.41 (+34.37%)

Apr 23, 2026

Company Details

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based ...

CEO

Paul D. Rubin

IPO Date

Sep 26, 2024

Website

bioagelabs.com

Key Metrics TTM

Revenue

$9M

— YoY

Net Income

-$81M

EPS (Diluted)

-$2.24

Free Cash Flow

-$82M

Revenue / Share

$0.25

Gross Margin

99.2%

Operating Margin

-1031.5%

Net Margin

-896.1%

FCF Margin

-915.5%

P/S

68.2x

P/E

—

Earnings Reports

Q1 2026

May 5, 2026

PENDING

FY 2025

Mar 24, 2026

$9MEPS -$2.24

Q4 2025

Mar 24, 2026

$3MEPS -$0.72

Q3 2025

Nov 6, 2025

$2MEPS -$0.56

Q2 2025

Aug 6, 2025

$2MEPS -$0.60

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 23	$0	$0	-$12M
Q2 23	$0	$0	-$13M
Q3 23	$0	$0	-$10M
Q4 23	$0	$0	-$14M
Q1 24	$0	$0	-$13M
Q2 24	$0	$0	-$15M
Q3 24	$0	$0	-$25M
Q4 24	$0	$0	-$25M
Q1 25	$1M	$1M	-$16M
Q2 25	$2M	$2M	-$25M
Q3 25	$2M	$2M	-$23M
Q4 25	$3M	$3M	-$28M

Valuation

Quarter	P/S	P/E
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	—	—
Q1 25	27.8x	—
Q2 25	38.3x	—
Q3 25	33.0x	—
Q4 25	55.2x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$10M	-$10M
Q2 23	-$11M	-$11M
Q3 23	-$8M	-$8M
Q4 23	-$9M	-$9M
Q1 24	-$16M	-$16M
Q2 24	-$16M	-$16M
Q3 24	-$15M	-$15M
Q4 24	-$5M	-$5M
Q1 25	-$17M	-$18M
Q2 25	-$20M	-$20M
Q3 25	-$16M	-$16M
Q4 25	-$28M	-$28M

Capital Expenditures

Quarter	CapEx
Q1 23	$11.0K
Q2 23	$56.0K
Q3 23	$99.0K
Q4 23	$0
Q1 24	$0
Q2 24	$35.0K
Q3 24	$305.0K
Q4 24	$26.0K
Q1 25	$426.0K
Q2 25	$159.0K
Q3 25	$22.0K
Q4 25	$112.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 24	—	+11.4%
Q2 24	—	+13.8%
Q3 24	—	+150.3%
Q4 24	—	+86.5%
Q1 25	—	+39.7%
Q2 25	—	+78.0%
Q3 25	—	+1.8%
Q4 25	—	+24.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$734.0K	—
Q2 23	$758.0K	—
Q3 23	$757.0K	—
Q4 23	$767.0K	—
Q1 24	$852.0K	—
Q2 24	$2M	—
Q3 24	$2M	—
Q4 24	$3M	—
Q1 25	$3M	203.2%
Q2 25	$3M	133.9%
Q3 25	$3M	135.9%
Q4 25	$3M	88.4%

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$8M	$3M
Q2 23	$9M	$4M
Q3 23	$7M	$3M
Q4 23	$10M	$4M
Q1 24	$9M	$3M
Q2 24	$10M	$5M
Q3 24	$20M	$5M
Q4 24	$19M	$6M
Q1 25	$11M	$7M
Q2 25	$20M	$7M
Q3 25	$19M	$7M
Q4 25	$25M	$7M

Revenue Segments

Quarter	Operating Segments
Q1 25	$1M
Q2 25	$2M
Q3 25	$2M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 23	$22M	$0	$22M
Q1 24	$174M	$0	$174M
Q2 24	$159M	$0	$159M
Q3 24	$334M	$0	$334M
Q4 24	$354M	$0	$354M
Q1 25	$257M	$63M	$321M
Q2 25	$220M	$77M	$297M
Q3 25	$216M	$70M	$286M
Q4 25	$189M	$92M	$281M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 23	7M	—	—
Q2 23	7M	+0.0%	—
Q3 23	7M	+0.0%	—
Q4 23	7M	+0.0%	—
Q1 24	7M	+0.0%	+0.0%
Q2 24	8M	+1.1%	+1.2%
Q3 24	3M	-53.7%	-53.2%
Q4 24	36M	+925.9%	+380.2%
Q1 25	36M	0.0%	+380.0%
Q2 25	36M	0.0%	+374.7%
Q3 25	36M	0.0%	+925.9%
Q4 25	36M	+0.2%	+0.2%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	$0	64
Q1 25	$22.7K	64
Q2 25	$37.7K	64
Q3 25	$32.1K	64
Q4 25	$49.6K	62

Revenue / Employee